2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1836

Standardized Incidence Ratio (SIR), Time Trend and Risk Factors of Avascular Bone Necrosis (AVN) in Patients with Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1936

STAT3-Regulated Gene Expression in Circulating CD4+ T Cells Discriminates RA Patients Independently of Clinical Parameters in Early Arthritis: A Validation Study

T cell Biology and Targets in Autoimmune Disease Poster I

9:00AM-11:00AM: Abstract Number: 1906

Stimulators of Soluble Guanylate Cyclase (sGC) Improve Wound Healing in the Tsk-1 Mouse Skin Fibrosis Mode

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 1905

Stimulators of Soluble Guanylate Cyclase (sGC) Inhibit Experimental Skin Fibrosis of Different Aetiologies

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster I

9:00AM-11:00AM: Abstract Number: 1304

Studying MR-Detected Inflammation in Symptom-Free Persons from the General Population to Generate Ramris-Based Reference Values

Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

9:00AM-11:00AM: Abstract Number: 1428

Subchondral Bone Structure and Pain Behaviors in Complete Freund’s Adjuvant (CFA) Monoarthritis in Mice Treated with Intra-Articular (IA) Neurotoxin

Pain: Basic and Clinical Aspects Poster

9:00AM-11:00AM: Abstract Number: 1700

Subclinical Atherosclerosis in Ankylosing Spondylitis. Does It Really Exist and Which Are the Effects of Treatments? a Systematic Review

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1709

Subclinical Atherosclerosis in Patients with Psoriatic Arthritis and the Role of Vitamin D

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1890

Subclinical Biventricular Systolic Function Is Impaired in Patients with Systemic Sclerosis with Real Time 3-D Echpcardiography: 1 Year Follow-up Study

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II

9:00AM-11:00AM: Abstract Number: 1409

Subglottic Stenosis: A Unique Inflammatory Disorder

Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

9:00AM-11:00AM: Abstract Number: 1541

Subgroups of Established Rheumatoid Arthritis Patients Can be Characterized By Patient and Physician Assessment Discrepancy, Anxiety and Depression and Presence of Depression Might be Associated with Slower Response to Treatment

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1397

Successful Treatment of Cardiac Sarcoidosis with Biologic and Immunosuppressive Combination Therapy

Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

9:00AM-11:00AM: Abstract Number: 1194

Support for Community-Based Programs for Managing Hip and Knee Osteoarthritis: Results of a Public Survey

Education Poster (ARHP): Education/Community Programs

9:00AM-11:00AM: Abstract Number: 1682

Suppression of Chronic Arthritis By a Novel Nuclear Factor of Activated T-Cell 5 (NFAT5) Inhibitor

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1138

Suppressor of Cytokine Signaling 1 Inhibits Interleukin-1β Induced Matrix Metalloproteinases Expression in Human Chondrocytes By Modulating p38-CREB- C/Ebpβ Pathway

Biology and Pathology of Bone and Joint Poster I: Osteoarthritis Pathogenesis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].